Abstract 948P
Background
Sitra, a spectrum-selective tyrosine kinase inhibitor, may enhance the efficacy of programmed cell death protein 1 (PD-1) inhibition. TIS, an anti-PD-1 antibody, has demonstrated efficacy in multiple advanced solid tumors. SAFFRON-104 is a multi-cohort Ph 1/2 study investigating sitra +/- TIS in patients (pts) with advanced HCC or GC/GEJC (NCT03941873).
Methods
Eligible pts had histologically/cytologically confirmed unresectable locally advanced or metastatic HCC or GC/GEJC. Pts enrolled in Ph 1 (dose escalation) received free base sitra (80 or 120 mg orally once daily) alone or combined with TIS (200 mg IV once every 3 weeks); Ph 1 determined the recommended Ph 2 dose (RP2D). Ph 2 evaluated sitra alone in pts with HCC who were naïve or refractory/resistant (R/R) to anti-PD-(L)1 therapy and sitra + TIS in pts with anti-PD-1/programmed death-ligand 1 (PD-L1)-naïve HCC, anti-PD-(L)1 R/R HCC, and anti-PD-(L)1-naïve GC/GEJC. Primary endpoints were safety/tolerability (Ph 1) and objective response rate (ORR) by RECIST v1.1 (Ph 2). Secondary endpoints included disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS).
Results
As of Jan 4, 2023, 111 pts were enrolled, of whom 102 were efficacy-evaluable (median study follow-up 9.1 months [range 0.7-34.0]). The RP2D of sitra determined in Ph 1 was 120 mg orally once daily. In pts receiving sitra +/- TIS, respectively, any-grade treatment-related adverse events (TRAEs) were reported in 74 (89.2%) and 24 (100%); ≥grade 3 TRAEs in 37 (44.6%) and 13 (54.2%); and serious TRAEs in 19 (22.9%) and 6 (25.0%). TRAEs leading to treatment discontinuation were reported in 10 (12.0%) pts and 1 (4.2%) pt receiving sitra +/- TIS, respectively. Pooled efficacy data from Ph 1 and 2 by indication are shown in the Table.
Conclusions
Sitra +/- TIS was generally well tolerated and showed preliminary antitumor activity in pts with advanced HCC and GC/GEJC.
Table: 948P
HCC | GC/GEJCa | |||
Treatment | Sitra | Sitra + TIS | Sitra + TIS | |
Prior anti-PD-(L)1 treatment | Naïve or R/R (n=20) | Naïve (n=26) | R/R (n=21) | Naïve (n=31) |
ORR, n (%) | 5 (25.0) | 3 (11.5) | 2 (9.5) | 5 (16.1) |
DCR, n (%) | 18 (90.0) | 22 (84.6) | 17 (81.0) | 22 (71.0) |
Median DoR, mo (95% CI) | 7.7 (2.8, NE) | 5.7 (4.1, NE) | NR (5.4, NE) | 5.5 (2.7, NE) |
Median PFS, mo (95% CI) | 6.8 (4.0, 7.4) | 6.8 (2.8, 8.3) | 4.2 (2.7, 6.8) | 3.6 (2.8, 4.7) |
Efficacy analysis set. aFour patients with GC/GEJC enrolled in Ph 1 were not included in the efficacy or safety analysis by indication because they were either anti-PD-(L)1 R/R or received sitra monotherapy. CI, confidence interval; mo, months; NE, not estimable; NR, not reached.
Clinical trial identification
NCT03941873 (first posted July 05, 2018).
Editorial acknowledgement
This study was sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Emily Finn, MSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
J. Li: Non-Financial Interests, Member: ASCO, CSCO. F. Yu, J. Zhang, Z. Zhang: Financial Interests, Full or part-time Employment: BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18